16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Titel:
16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
Auteur:
Moreno, V. Braña, I. Sepulveda Sanchez, J.M. Vieito Villar, M. Hernández Guerrero, T. Doger, B. Saavedra, O. Pinto, A. Carlo Stella, C. Italiano, A. Michot, J-M. Musuraca, G. Sarmiento, R. De Alvaro, J. Zuraek, M. Sánchez-Pérez, T. Aronchik, I. Filvaroff, E. Hanna, B. Nikolova, Z.